AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
Comes After Delay For Roxadustat In The US
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.
